Literature DB >> 7356431

Rhabdomyolysis during treatment with epsilon-aminocaproic acid.

C W Britt, R R Light, B H Peters, S S Schochet.   

Abstract

Severe rhabdomyolysis and acute renal failure occurred in a patient receiving epsilon-aminocaproic acid. The lack of evidence of vascular involvement in the muscle biopsy specimen suggests that epsilon-aminocaproic acid may have direct myotoxicity. This drug may produce a spectrum of muscle disease from mild myopathy to life-threatening rhabdomyolysis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7356431     DOI: 10.1001/archneur.1980.00500520085021

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  5 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

Review 2.  Antifibrinolytic agents in subarachnoid haemorrhage.

Authors:  K W Lindsay
Journal:  J Neurol       Date:  1987-01       Impact factor: 4.849

Review 3.  Adverse effects of drugs on muscle.

Authors:  F L Mastaglia
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

Review 4.  Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage.

Authors:  Mark Chwajol; Robert M Starke; Grace H Kim; Stephan A Mayer; E Sander Connolly
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

5.  Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.

Authors:  G Galassi; M Gibertoni; L Corradini; A Colombo
Journal:  Ital J Neurol Sci       Date:  1983-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.